Ann Moore
Nurse Practitioner · Glendale, AZNPI 1184840712
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Gilead at 25.8% of the total. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 615 payments — averaging $337.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54K
- Intercept Pharmaceuticals, Inc.$44K
- AbbVie$41K
- Ipsen Biopharmaceuticals, Inc$24K
- GSK$16K
- Madrigal Pharmaceuticals$12K
- plus $17K from 20 others
Across 565 payments — averaging $3343.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Madrigal Pharmaceuticals$1.5M
- Novo Nordisk AS$309K
- Corcept Therapeutics$66K
- Gilead$15K
What the payments were for
- Consulting fees$36,82718%
- Speaking & faculty fees$114,62155%
- Travel & lodging$41,02420%
- Food & beverage$15,3007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 176 | $53,682 |
| Intercept Pharmaceuticals, Inc. | 84 | $44,214 |
| AbbVie | 148 | $40,669 |
| Ipsen Biopharmaceuticals, Inc | 51 | $23,933 |
| GSK | 11 | $15,923 |
| Madrigal Pharmaceuticals | 44 | $12,297 |
| Siemens Medical Solutions USA, Inc. | 7 | $7,010 |
| Novo Nordisk | 7 | $3,810 |
| Albireo Pharma, Inc. | 2 | $2,888 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $1,603 |
| Ipsen Innovation | 1 | $665 |
| Amgen | 23 | $499 |
| Orphalan Inc | 4 | $97 |
| AstraZeneca | 3 | $75 |
| Mirum Pharmaceuticals, Inc. | 3 | $67 |
| Eisai Inc. | 3 | $55 |
| Boston Scientific | 2 | $48 |
| Merck | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Trisalus Life Sciences, Inc. | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Intra-sana Laboratories | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$43,316
- Mavyret$37,156
- Epclusa$28,893
- IQIRVO$16,629
- Livdelzi$11,459
- REZDIFFRA$11,082
- Bylvay$9,755
- Atellica IM 1300 Analyzer$4,910
- ADVIA Centaur XP Analyzer$1,600
- TRULANCE$900
- XIFAXAN$900
- RESMETIROM$150
- Descovy$103
How this compares
$207,771 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 68 | $1,747,557 |
| XifaxanRifaximin | 62 | $224,372 |
| RezdiffraResmetirom | 33 | $132,696 |
| VemlidyTenofovir Alafenamide | 18 | $34,178 |
| Ursodiol | 94 | $29,621 |
| Tacrolimus | 14 | $2,831 |
| Mycophenolate Mofetil | 11 | $1,392 |
| Lactulose | 24 | $1,014 |
| Spironolactone | 31 | $238 |
| Carvedilol | 29 | $210 |
| Furosemide | 17 | $99 |
| Prednisone | 16 | $74 |
| Pantoprazole Sodium | 18 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $53,682 | $1,781,73486 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,603 | $224,37262 claims |
| Madrigal PharmaceuticalsRezdiffra | $12,297 | $132,69633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Glendale
- Ronalyn BaricevicGlendale$12K
- Shayla JohnsonGlendale$9K
- Bea Paula SalvaneraGlendale$9K
- Sandra KurtinTucson$201K
- Kristen HerzogScottsdale$162K
- Krista ArredondoChandler$133K
- Shannon MorgensternOro Valley$71K
- Helena In't VeldPhoenix$64K
- Steven KalfusChandler$43K
- Dustin NickersonPhoenix$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.